Recursion Pharmaceuticals第二季度运营收入730.3万美元,低于IBES预期1190万美元

投资观察
Aug 05

Recursion Pharmaceuticals(RXRX)公布了第二季度财务数据。其运营收入仅为730.3万美元,远低于IBES估算的1190万美元。此外,该公司在报告期内录得税前亏损1.31006亿美元。这一业绩表现与市场预期存在显著差距,反映出公司当前面临的挑战。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10